title: [Neoadjuvant treatment in human epidermal growth factor receptor 2-positive breast cancer].
abstract: Breast cancer is the most prevalent malignancy among females worldwide. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer represents a subtype with aggressive behavior, poor response to treatment and unfavorable prognosis. Anti-HER2-based neoadjuvant treatment has improved clinical outcomes of patients with HER2-positive disease. Pathological complete response (pCR) after neoadjuvant treatment indicates a favorable prognosis. With the development of HER2-targeted therapy and neoadjuvant treatment, numerous studies focus on the predictive factors of pCR or therapeutic resistance of anti-HER2 therapy. Identification of novel predictive factors in HER2-positive breast cancer, such as tumor-infiltrating lymphocytes, will be helpful for clinical decision.
authors: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors: Yinhua
authors: Y
authors: Liu
authors: Breast Disease Center, Peking University First Hospital, Beijing 100034, China; Email: congzhongfeixiang@163.com.
authors: Shiwei
authors: S
authors: Liu
authors: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors: Hong
authors: H
authors: Zhang
authors: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors: Ling
authors: L
authors: Xu
authors: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors: Ting
authors: T
authors: Li
authors: Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
authors: Xuening
authors: X
authors: Duan
mesh_terms: D001943:Breast Neoplasms; D006801:Humans; D020360:Neoadjuvant Therapy; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human